Tempero Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for substance use disorders (SUDs) and related conditions. Their lead therapeutic candidate, TMP-301, is a potent, orally-available negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5). This technology aims to address the critical need for effective medications in treating SUDs, particularly Cocaine Use Disorder (CUD) and Alcohol Use Disorder (AUD). TMP-301 works by selectively modulating glutamate signaling in specific brain regions associated with addiction, thereby offering a novel approach to managing these disorders.

The company is focused on advancing TMP-301 through various stages of clinical development, with ongoing research into its potential applications for other addictive disorders, including Opioid Use Disorder (OUD) and Polysubstance Use Disorder (PUD). Tempero Bio's commitment to translating scientific advancements into effective therapies is underscored by their operational resources and leadership team, which are geared towards addressing the significant treatment gap in the addiction crisis. Their efforts are particularly timely, given the alarming rise in overdose deaths and the urgent need for new treatment options in the field of addiction medicine.

United States

Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for substance use disorders and related conditions.

Tempero Bio

Company Details